Peerview Clinical Pharmacology Cme/cne/cpe Audio Podcast

Go online to PeerView.com/NRG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. HER2-low breast cancer, currently defined as HER2 IHC 1+ or 2+/ISH-, accounts for approximately 50% of all breast cancers. While older HER2-targeted therapies did not show efficacy in HER2-low breast cancers, novel antibody–drug conjugates (ADCs) have demonstrated remarkable activity in this setting. Because of these advances and the FDA approval of the first HER2-targeting ADC for HER2-low breast cancer, there is an urgent need to rethink the approaches to HER2 testing so that patients with HER2-low breast cancer could be identified and get a chance to benefit from the new therapeutic approach. The understanding, definitions, and testing for HER2-low status continue to evolve, and many practical challenges and unanswered questions remain. This PeerView educational activity, based on a recent live symposium, explores the most cutting-edge information on HER2-low breast cancer, p

Go online to PeerView.com/XFA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in HIV prevention and a patient advocate discuss the benefits of pre-exposure prophylaxis (PrEP) and the necessary tools for engaging patients in conversations about sexual health practices as well as strategies for improving the uptake of HIV prevention measures. Upon completion of this activity, participants should be better able to: Effectively engage clients in conversations about sexual health practices to assess HIV risk factors and support their ability to have healthy sex lives; Apply current evidence with individual client needs/preferences when integrating HIV prevention options (eg, PrEP, PEP, viral suppression, female condoms) into practice; Employ culturally competent educational and counseling strategies to improve the uptake of prevention measures among clients at increased risk for HIV infection; and Describe currently available and emer

Go online to PeerView.com/DCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The time has come for even more precision in testing and targeted treatment of NSCLC. EGFR-mutated lung cancer is a perfect example of this need. The term "EGFR-positive lung cancer” is no longer adequate or specific enough to characterize this complex molecular subtype of lung cancer. Increased granularity is needed for both biomarker testing and targeted treatment selection for patients with different types of EGFR mutations. New agents and combinations have become available for patients with common (eg, exon 19 deletion, exon 21 L858R) and uncommon (eg, exon 20 insertions) EGFR mutations, and more are on the horizon. Novel strategies for overcoming resistance to EGFR-targeted therapies are showing great promise as well. This PeerView Live educational activity, based on a recent live symposium, explores the latest advances and future directions in biomarker-driven, individuali

Go online to PeerView.com/NHA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immunotherapy is now a highly efficacious management tool for melanoma, including in resectable stage III/IV disease, where its use is supported by phase 3 evidence and current practice guidelines. This “Clinical Consults” activity, taken from a recent surgical oncology live event, features expert-led case discussions that illustrate how to deliver effective care with established and emerging immune-based modalities in surgical settings. Linked mini lecture segments cover topics such as adjuvant immunotherapy in stage II/III melanoma; efficacy, safety, and dosing information on neoadjuvant immunotherapy; and emerging immune-based treatments in resectable melanoma (eg, PD-1/LAG-3 combinations). Watch today to learn how to identify optimal candidates for immunotherapy, address treatment selection and dosing considerations, and effectively manage immune-related events. Upon complet

Go online to PeerView.com/RGA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Although the prognosis of patients with early breast cancer (EBC) has improved with earlier detection and more efficacious therapies, many patients still face poor outcomes, and there is an urgent need to prevent recurrences. An increasing number of systemic therapies have been recently approved in the perioperative settings of HR+, HER2+, and triple-negative breast cancer (TNBC), including immunotherapy, CDK4/6 inhibitor therapy, adjuvant PARP inhibitor therapy, and a number of HER2-targeted therapies. Other agents and combinations are undergoing evaluation in clinical trials and are likely to expand the systemic therapy arsenal for patients with EBC. With the increasing complexity of systemic and local treatment of patients with EBC, it is crucial for surgeons, medical oncologists, pathologists, and other members of the breast cancer care team to effectively collaborate and co

Go online to PeerView.com/YTW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What are your thoughts on the latest diagnostic guidelines and therapeutic gains for the treatment of recurrent or advanced endometrial cancer (EC)? This PeerView Live MasterClass & Practicum, based on a recent live event, showcases expert perspectives on the scientific rationale and shares practical guidance for incorporating molecular testing into the management of patients with recurrent or advanced EC. In-depth updates on efficacy and safety data for approved and emerging immunotherapeutic regimens are paired with case-based discussions of best practices for bringing individualized treatment plans to the clinic. Upon completion of this activity, participants should be better able to: Describe the rationales, therapeutic roles, and key efficacy/safety evidence of immunotherapy-based options for patients with recurrent or advanced endometrial cancer; Integrate new and emer

Go online to PeerView.com/XPM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to implement advances with targeted agents in CLL in your pharmacy practice? Find out by viewing this “Pharmacy MasterClass & Case Forum” program, recorded during the 2023 Hematology/Oncology Pharmacy Association (HOPA) 19th Annual Conference. Throughout, expert pharmacists will present state-of-the-art evidence supporting the use of highly efficacious targeted strategies in CLL, including covalent and non-covalent BTK inhibitors, BCL2 inhibitors, and chemo-sparing combinations, and give insights on how to apply the evidence supporting these strategies to real-world practice. The experts will also prepare you to anticipate and manage adverse events; proactively address drug interaction and dosing complexities; and provide staff and patient education on single-agent and combination strategies. Don’t miss this opportunity to get the latest on the new treatment

Go online to PeerView.com/FPT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you fully prepared as we move further into the immune checkpoint inhibitor (ICI) era in early-stage bladder cancer? Already well established in metastatic urothelial carcinoma, the role of ICIs has now been validated and resulted in regulatory approvals in both non–muscle-invasive bladder cancer (NMIBC) and high-risk muscle-invasive bladder cancer (MIBC). In this interdisciplinary discussion, two bladder cancer experts provide practical guidance on the use of ICIs in the treatment of patients with early-stage bladder cancer, including as part of bladder-sparing and perioperative approaches. Hear about accumulating evidence on these agents and learn guideline-based strategies for incorporating immunotherapy into personalized treatment plans and collaborating with other members of the cancer care team to manage immune-related adverse events and improve outcomes for your patien

Go online to PeerView.com/CDT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prurigo nodularis (PN) is a chronic inflammatory skin condition marked by intensely pruritic, hyperkeratotic nodules distributed on the trunk and extremities. Severe itching contributes to scratching, bleeding, thickening of nodules, and scarring. PN can significantly reduce quality of life, affect sleep and mental health, and hamper participation in activities of daily living and social interaction. Until recently, there were no approved treatments for PN, but one agent has been granted a PN indication, and others are in late-stage development. In this activity, based on a recent live symposium, a panel of experts offers personal guidance on the pathophysiology, burden, and new and promising treatment options for PN. The discussion is enhanced by 3D animation depicting PN pathophysiology plus patient videos that provide compelling perspectives on the burdens of the disease and

Go online to PeerView.com/WEZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Modern care of hepatocellular carcinoma (HCC) is increasingly reliant on collaboration between interventional radiology and oncology to select, combine, sequence, and transition between therapy options. In this activity, based on a recent webcast event, case-based discussions are used to explore best practices for managing patients through interdisciplinary collaboration. Experts discuss innovative immunotherapy and locoregional therapy options in earlier-stage disease, the transition to systemic therapy in advanced disease, and explore the latest clinical and safety data in immunotherapy-antiangiogenic regimens, dual checkpoint inhibitor approaches, and newer single-agent immune options. Upon completion of this activity, participants should be better able to: Cite current evidence supporting immunotherapy-based platforms in advanced and intermediate HCC; Integrate immunotherapy

Go online to PeerView.com/JPU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Observed differences in healthcare disparities for patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN) have led to the recognition of racial and ethnic minorities as an independent predictor of worse disease outcomes in SLE/LN. Earlier diagnosis, earlier intervention, treatment strategies targeted to clinical remission or low disease activity, and effective communication and collaboration between providers and patients could offer the opportunity to reduce damage, thus improving long-term outcomes. Through a collection of short, focused educational modules, this PeerView activity allows learners to combine self-assessment with concise clinical content in an interactive format. Drs. Sheikh and Rovin will explore the emerging concept of treat to target, as well as the use of currently available and new/emerging biologic therapies, along with strategies to he

Go online to PeerView.com/XSA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to leverage the benefits of the wide range of newly approved therapeutics that are revolutionizing patient care in AML? Find out in this “Clinical Consults” activity based on a recording at the 2023 USCAP Annual Meeting. A pathologist and a hematologist-oncologist team up to discuss how modern diagnostic techniques can lead to better, more collaborative, personalized care using novel therapeutics to manage challenging AML cases (including in high-risk and mutation-defined AML) and use cases to illustrate diagnostic testing techniques and how pathology and hem-onc can collaborate on treatment decision-making. Watch this video activity today and hear how pathologists and hematologist-oncologists can team up for better outcomes! Upon completion of this activity, participants should be better able to: Discuss the cytogenetic and histopathologic features that enable dia

Go online to PeerView.com/UKX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to work collaboratively to overcome the complexities of myelodysplastic syndromes (MDS) diagnosis, prognostic assessment, and individualized therapy selection? Find out by joining pathology and hematology-oncology experts in this activity, based on a live symposium, that offers case-based guidance on modern, personalized treatment for patients with different disease presentations. Throughout, the experts illustrate how to address important disease symptoms (such as anemia) and reinforce the core pathology principles for optimized diagnosis and communication of test results with a goal in prodigy enhanced, more personalized care. Upon completion of this activity, participants should be better able to: Discuss molecular and pathologic features, risk factors, and evidence supporting the use of novel therapeutics to inform diagnostic assessment and personalized care

Go online to PeerView.com/ZXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the importance of early detection and diagnosis of ALS, advances in genetic testing and biomarker development, and current and emerging therapeutic approaches for patients with ALS, as well as the benefits of employing a multidisciplinary approach in managing patients with ALS. Upon completion of this activity, participants should be better able to: Identify common genes and cellular processes implicated in ALS pathogenesis; Apply established criteria to detect and diagnose patients with ALS early in the disease course; Assess key data sets on contemporary and emerging evidence-based treatment options to manage symptoms and improve the quality of life of patients with ALS; and Employ a multidisciplinary team-based approach to optimize the management of ALS based on the individual needs and preferences of each patient.

Go online to PeerView.com/GYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease and has a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. The FDA has recently approved a noninvasive, first-in-class cardiac myosin inhibitor specifically indicated for the treatment of HCM—meaning timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment. In this activity, based on a recent live symposium, expert panelists present practical skills and guidance to accurately diagnose HCM and apply recent treatment advances to patients with various clinical presentations of HCM. They begin by sharing the rationale for maintaining a high index of suspicion for HCM and review diagnostic strategies. The Clinical Consults portion of this activity features case examples to demonstrate current practices

Go online to PeerView.com/CJR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Preventing and managing graft-versus-host disease (GVHD) remains a significant problem in the post–allogeneic hematopoietic stem cell transplant (HCT) setting. Can a wide range of unique treatment modalities, including costimulatory compounds, targeted agents, and engineered cell therapy, challenge long-standing management protocols in this setting? Find out in this activity, based on a recent live symposium, which features an overview of available and emerging therapeutic options for modern GVHD management as a means to extend the benefits of HCT and provide more effective prophylaxis and treatment. Upon completion of this activity, participants should be better able to: Summarize current safety/efficacy evidence supporting the use of novel therapeutics for prophylaxis or treatment of acute or chronic graft-versus-host-disease (GVHD) in the post-transplant setting; Develop mana

Go online to PeerView.com/AQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Late-onset Alzheimer’s disease (LOAD) has a substantial genetic component, with heritability estimated to be between 40% and 80%, and the APOE ε4 allele is the strongest individual genetic risk factor for LOAD. Until recently, the APOE genotype test has been primarily used as a research tool and not recommended for clinical use. However, with the recent advances in disease-modifying therapies (DMTs), including several anti–amyloid monoclonal antibodies approved or in late-stage development, it is more important to determine which patients have the APOE ε4 allele and whether these patients are at an elevated risk of developing amyloid-related imaging abnormalities (ARIA). In this activity, based on a recent live webcast, experts examine the significance of APOE ε4 carrier status on the risk for developing LOAD, as well as the potential implications for patient care, including the

Go online to PeerView.com/AYK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hepatology discusses the importance of early detection of hepatitis B virus (HBV) infection and presents current and evolving screening, vaccination, and treatment guidelines. The expert emphasizes the role of primary care providers in managing patients with chronic HBV and in helping to reach the WHO goal of eliminating viral hepatitis as a public health threat by 2030 through vaccination, screening, and patient education. Finally, the expert clarifies when patients with chronic HBV infection should be referred for specialty care. Upon completion of this activity, participants should be better able to: Describe the burden and consequences of HBV infection and how chronic HBV can lead to end-stage liver disease and hepatocellular carcinoma; Identify patients who should be screened for HBV, which tests should be ordered, and how to interpret the res

Go online to PeerView.com/GNU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the continued expansion of the cancer immunotherapy arsenal, reliable biomarkers to identify patients most likely to benefit from specific agents or combinations have become crucial. Predictive biomarkers such as measurement of PD-L1 expression and assessment of MSI/MMR or TMB status have an established role in some tumor types and settings, but a number of challenges related to testing and interpretation of results persist, and significant improvements are needed. There is also a need for ways to assess response to immunotherapies as they transition to early-stage, curative-intent settings as part of perioperative multimodal management of solid malignancies. Recently, pathologic response assessment has emerged as a potential new gold standard for measurement of impact of neoadjuvant immunotherapy. However, there has been limited guidance on how to define pathologic respons

Go online to PeerView.com/WQZ_1860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Implementing guideline-recommended anticoagulation therapy is vital to prevent stroke in individuals with atrial fibrillation (AF). Through a MasterClass series of seven episodes, two expert cardiologists examine risk factors, screening strategies, and data from clinical trials, as well as real-world evidence, to offer best practices to detect and treat AF. Upon completion of this activity, participants should be better able to: Describe the impact and burden of undiagnosed AF on the prevalence of stroke and other cardiovascular events, and ultimately on the healthcare system and society; Implement interprofessional screening strategies to increase rates of AF diagnosis in at-risk patients, in accordance with guidelines and leveraging advances in technology; and Develop personalized, evidence-based anticoagulant treatment plans for patients diagnosed with AF using clinical tri